Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 30
- Registration Number
- NCT00276809
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Universitatsklinikum Heidelberg, Heidelberg, Germany
🇩🇪University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany
Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 169
- Registration Number
- NCT00275015
- Locations
- 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany
🇩🇪Internistische Praxis - Trier, Trier, Germany
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00244946
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2017-09-28
- Target Recruit Count
- 44
- Registration Number
- NCT00242996
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 98
- Registration Number
- NCT00233987
- Locations
- 🇺🇸
Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States
🇺🇸Associates in Womens Health, PA - North Review, Wichita, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- European Mantle Cell Lymphoma Network
- Target Recruit Count
- 360
- Registration Number
- NCT00209222
- Locations
- 🇫🇷
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
🇩🇪German Low Grade Study Group (Glsg), Munich, Germany
🇵🇱The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 481
- Registration Number
- NCT00137995
- Locations
- 🇮🇱
Israel Society of Hematology, Tel-Hashomer, Israel
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇫🇮Hospital district of south west Finland, Turku, Finland
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
- Conditions
- First Posted Date
- 2004-08-16
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 45
- Registration Number
- NCT00003400
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
- Conditions
- First Posted Date
- 2004-08-16
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 56
- Registration Number
- NCT00003348
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2004-08-16
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00003543
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.